|
Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors Clinical research trials and Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors. Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors  Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors
Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Norris Cotton Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PEG-interferon alfa-2B may interfere with the growth of cancer cells. Combining temozolomide with PEG-interferon alfa-2B may be an effective treatment for advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and PEG-interferon alfa-2B in treating patients who have advanced solid tumors.
Details: OBJECTIVES: I. Determine the safety and tolerability of temozolomide and PEG-interferon alfa-2b in patients with advanced refractory solid tumors or chemotherapy-naive advanced cancer. II. Determine the maximum tolerated dose (MTD) and dose-limiting toxicity of this regimen in this patient population. III. Determine the pharmacokinetics of PEG-interferon alfa-2b at the MTD when administered with temozolomide in this patient population. IV. Determine the anti-tumor activity of this regimen in these patients. PROTOCOL OUTLINE: This is a dose-escalation study. Patients receive oral temozolomide on days 1-7 and 15-21 and PEG-interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 1-9 patients receive escalating doses of temozolomide and PEG-interferon alfa-2b until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A maximum of 24 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed advanced solid tumor that is refractory to standard therapy OR Histologically confirmed chemotherapy-naive advanced cancer for which no curative therapy or higher priority palliative chemotherapy exists Brain metastasis allowed No bone marrow involvement of tumor --Prior/Concurrent Therapy-- Biologic therapy: - At least 3 weeks since prior biologic agents (e.g., bi-specific antibodies, interleukin-2, or interferon) and recovered (excluding alopecia) - No prior allogeneic, syngeneic, or autologous bone marrow or stem cell transplantation - No other concurrent biologic therapy - No concurrent colony stimulating factors or epoetin alfa for the prevention of myelotoxicity Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy (more than 6 weeks for nitrosoureas, melphalan, or mitomycin) and recovered (excluding alopecia) - No prior high-dose chemotherapy and stem cell transplantation - No more than 3 prior chemotherapy regimens - No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: - At least 6 weeks since prior wide-field radiotherapy to at least 25% of bone marrow (e.g., pelvic radiotherapy) - More than 6 weeks since prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium - Recovered from prior radiotherapy (excluding alopecia) - No concurrent radiotherapy Surgery: - At least 4 weeks since prior major surgery - At least 1 week since prior minor surgery Other: At least 4 weeks since prior investigational therapy --Patient Characteristics-- Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: - Absolute neutrophil count greater than 1,500/mm3 AND/OR - Platelet count greater than 100,000/mm3 Hepatic: - ALT or AST less than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present) - No autoimmune hepatitis Renal: Creatinine less than 2.5 times ULN Cardiovascular: - No severe coronary artery disease - No congestive heart failure Pulmonary: No severe chronic obstructive pulmonary disease Gastrointestinal: - No frequent vomiting - No medical condition that would interfere with oral medication intake (e.g., partial bowel obstruction, partial intestinal bypass, or external biliary diversion) Other: - No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No known or suspected hypersensitivity to imidazotetrazin, interferon alfa, or any excipient or vehicle included in the formulation or delivery system of study drug - No history of autoimmune disease - No preexisting severe psychiatric condition or history of severe psychiatric disorder (including suicidal ideation or attempt) - No life-threatening condition or severe preexisting condition - No uncontrolled thyroid abnormalities - No nonmalignant systemic disease - No active uncontrolled infection - HIV negative - No AIDS-related illness - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LionelLewis, Study Chair, Norris Cotton Cancer Center
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
United States
Additional Information:
Study ID Numbers: CDR0000068523; NCI-G01-1924,DMS-0010
Study Start Date: October 2000
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00014261
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors
2. Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer
3. Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
4. DHA-Paclitaxel With or Without Gemcitabine in Treating Patients With Advanced Solid Tumors or Unresectable Pancreatic Cancer
5. R115777 in Treating Patients With Advanced Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other New Hampshire Clinical Trials
Other Lebanon Clinical Trials
Temozolomide plus PEG-Interferon alfa-2B in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
